TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05212051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study: NCT04977739

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT05212051

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study: NCT05067270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog diluent
Description: Administered SC infusion.
Study: NCT05212051

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study: NCT05230147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
Study: NCT06105138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg Cannabidiol oral solution
Description: 200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 30mg Cannabidiol oral solution
Description: 30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%.
Study: NCT06154629

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical ingredient
Description: Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
Study: NCT05067270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog diluent
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog diluent
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog diluent
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog diluent
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: Administered SC infusion.
Study: NCT05574140

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
Study: NCT05153343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 25mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 50mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 100mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 150mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 225mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 325mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study: NCT06217991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTST(parachute-tunnel-style technique)for esophagogastrostomy
Description: Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
Study: NCT05018286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
Study: NCT06129084

Intervention type: GENETIC
Intervention: FGFR Testing
Description: Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
Study: NCT05067270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: Administered SC infusion.
Study: NCT06075732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
Study: NCT06573853

Intervention type: PROCEDURE
Intervention: Focal Pulsed Field Ablation (PFA)
Description: Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.

Intervention type: PROCEDURE
Intervention: Focal Radiofrequecy Ablation (RFA)
Description: Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
Study: NCT06441630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-227A
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-227A
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-227A
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-227B
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study: NCT06036238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Intervention (HLI)
Description: The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
Study: NCT06441630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-227C
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-227B
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-227B
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-227C
Description: Per Oral, 1 Tablet, Once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-227C
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study: NCT04820179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib + Atezolizumab
Description: All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
Study: NCT05794139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets
Study: NCT06544239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality basketball asymmetric training
Description: This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
Study: NCT05937776

Intervention type: OTHER
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: OTHER
Intervention: Gadoterate Meglumine
Description: Given IV
Study: NCT06036238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
Study: NCT05347355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spencer technique along with conventional treatment
Description: Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gongs Mobilization along with conventional treatment
Description: The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
Study: NCT05937776

Intervention type: PROCEDURE
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo PET/contrast-enhanced MRI
Study: NCT06544239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional basketball asymmetric training
Description: This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
Study: NCT05937776

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET/contrast-enhanced MRI
Study: NCT04097743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Statement
Description: Daily practice of coping statement
Study: NCT04109599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart
Description: Participants played the developed PlaySmart game over the course of a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart
Description: Participants played the developed PlaySmart game over the course of a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Smart Mini-Game
Description: Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
Study: NCT05059288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Non Invasive Ventilation Mask
Description: Oronasal non invasive ventilation mask
Study: NCT06372743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTEGREAT-CKD Intervention
Description: The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status.
Study: NCT04653896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeogo
Description: The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
Study: NCT05676710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation.
Study: NCT05680805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 1500 mg/day in 3 divided dose for 24 weeks
Study: NCT05240261

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: Quetiapine 25 mg / day
Study: NCT04941443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Pill
Description: All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.